Do I need a prescription for Loratadine 10mg tablets?

Loratadine 10mg tablets is classified as a Valid as a prescribable product in the UK. However, always consult a pharmacist or doctor before use. (Source: NHS dm+d)

What are the brand names for Loratadine 10mg tablets?

Loratadine 10mg tablets is the generic name. It is available under brand names including: Bell's Hayfever & Allergy Relief 10mg tablets, Boots One A Day Allergy Relief 10mg tablets, Brown & Burk Once-A-Day Hayfever & Allergy 10mg tablets, Clarityn Allergy 10mg tablets, Galpharm Non-Drowsy Allergy Relief 10mg tablets and 33 more. (Source: NHS dm+d — Actual Medicinal Products)

Loratadine 10mg tablets

Prescription only

Requires a prescription from a doctor or prescriber

Tablet

10mg

Oral

Antihistamines, hyposensitisation, and allergic emergencies

Active ingredients:

Loratadine

BNF classificationBrowse formulary

Where this medicine sits in the British National Formulary — the UK's standard prescribing reference

BNF 03.04.01

ATC classificationBrowse ATC index

International classification by the WHO, grouping medicines by the organ system they act on

ATC R06AX13

Chemical classBrowse classes

Classification based on the molecule's chemical structure and properties

Check interactions for Loratadine

No active safety alerts

Official documents, adverse reaction reporting, and safety monitoring

Report a side effect

Submit a Yellow Card report to the MHRA

Official medicine documents

Yellow Card

Report side effects (MHRA)

Drug safety updates

MHRA alerts for Loratadine

Source: MHRA Products DatabaseOGL 3.0

Updated 3 months ago(16 Jan 2026)

Safety monitoring data

Yellow Card reports

MHRA

The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.

View Drug Analysis Profile

Suspected adverse reactions reported for Loratadine

Browse all iDAP reports

Interactive Drug Analysis Profiles for all medicines

Report a side effect

Submit a Yellow Card report to the MHRA

Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.

EudraVigilance

EMA

The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.

View EudraVigilance report

Suspected adverse reactions reported for Loratadine

About EudraVigilance

Learn about EU pharmacovigilance and safety monitoring

EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.

38 branded products available

38 productsShow details

Part of the Clarityn brand family (generic: Loratadine)

38 products

Possibly available on the UK marketDiscontinuedAvailability per NHS dm+d

MHRA licensed products

View all licensed products for Loratadine on the MHRA register

Bell's Hayfever & Allergy Relief 10mg tablets

Bell,Sons & Co (Druggists) Ltd

Boots One A Day Allergy Relief 10mg tablets

The Boots Company Plc

Brown & Burk Once-A-Day Hayfever & Allergy 10mg tablets

Brown & Burk UK Ltd

Clarityn Allergy 10mg tablets

Bayer Plc

Numark Allergy & Hayfever 10mg tablets

Numark Ltd

Loratadine 10mg tablets

Accord-UK Ltd

Loratadine 10mg tablets

Teva UK Ltd

Loratadine 10mg tablets

A A H Pharmaceuticals Ltd

Loratadine 10mg tablets

Alliance Healthcare (Distribution) Ltd

Loratadine 10mg tablets

Sun Pharma UK Ltd

Loratadine 10mg tablets

Sigma Pharmaceuticals Plc

Loratadine 10mg tablets

Phoenix Healthcare Distribution Ltd

Source: NHS dm+dOGL 3.0

Updated about 1 month ago(1 Mar 2026)

Price & daily doseShow details

£0.66indicative price

This is the NHS Drug Tariff indicative price used for reimbursement purposes. It may not reflect the price paid by patients or pharmacies.

View full Drug Tariff

Source: NHS Drug Tariff via NHSBSA. Derived from dm+d VMPP (Virtual Medicinal Product Pack) pricing data. Contains public sector information licensed under the Open Government Licence v3.0.

WHO defined daily dose (DDD)

10 mg

Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.

Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via NHS dm+d BNF mapping files. Contains public sector information licensed under the Open Government Licence v3.0.

Therapeutically similar medicines

10 similarShow details

Fexofenadine 30mg/5ml oral suspension

Oral suspension

30mg/5ml

Same therapeutic group

Bilastine 2.5mg/ml oral solution sugar free

Oral solution

2.5mg

Same therapeutic group

Bilastine 10mg orodispersible tablets sugar free

Tablet

10mg

Same therapeutic group

Loratadine 5mg/5ml oral solution sugar free

Oral solution

5mg/5ml

Same therapeutic group

Rupatadine 1mg/ml oral solution

Oral solution

1mg

Same therapeutic group

Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.

NHS prescribing volume and spending trends

Show details

Loading prescribing data...

Clinical guidelines and formulary information

British National Formulary

Loratadine

BNF

Drug monograph — bnf.nice.org.uk

Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.

NICE clinical guidance(1)

Insect bites and stings: antimicrobial prescribing (NG182)

NG182

Guidance

Updated Sept 2020

Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.

Check stock at pharmacies and supply information

Show details

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

DeliveryNHS

P2U

Pharmacy2U

Search products

DeliveryNHS

Supply & product information

Official product databases and supply status monitoring

Shortages info

NHS Specialist Pharmacy Service (SPS)

emc product search

Discontinuations & alternatives for Loratadine

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.

Codes for healthcare professionals and prescribing systems

Show details

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

42192711000001108

dm+d ID

42192711000001108

VTM (Virtual Therapeutic Moiety)

776572007

VMP (Virtual Medicinal Product)

42192711000001108

BNF code

03040100

International identifiers

ATC code — Anatomical Therapeutic Chemical (WHO)

R06AX13

Browse tools

dm+d Browser

NHSBSA medicines dictionary lookup

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).

Active and completed clinical studies from ClinicalTrials.gov

Show details

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

None known

Half-life

10 hours

Mechanism

Histamine release is a key mediator in allergic rhinitis and urticaria.

Food interactions

None known

Human targets

2 targets

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Absorption

1-2 hours

Loratadine is rapidly absorbed and achieves peak plasma concentration in 1-2 hours, while it's main metabolite achieves peak plasma concentration in 3-4 hours.
[A176438]

In…

Half-life

10 hours

The elimination half life is approximately 10 hours for loratadine and 20 hours for descarboethoxyloratadine.
[A176438]

Protein binding

97 - 99%

97 - 99% of the loratadine is bound to plasma proteins.
[L8486]

Volume of distribution

120 L/Kg

The volume of distribution of loratadine is 120 L/Kg.
[L8618]

Metabolism

Loratadine undergoes extensive first pass metabolism in the liver and is primarily metabolized by CYP3A4, CYP2D6, CYP1A1 and CYP2C19.…

Elimination

10 day

Over a 10 day period, 40% of loratadine is excreted in the urine, and 42% is eliminated in the faeces.
[L8486]

Clearance

20 mg

The clearance of loratadine after single oral doses of 20 mg and 40 mg are 12 L/h/kg and 9 L/h/kg respectively.
[A5506]…

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Investigational

Small molecule

About this compound

Loratadine is a second generation antihistamine used to manage symptoms of allergic rhinitis.[A176435] A lack of sedative and CNS adverse effects make loratadine, along with other second generation antihistamines, preferable over their 1st generation counterparts in many clinical situations.[A176441]

Properties:

solid

Avg. mass: 382.88 Da

DrugBank indication

Loratadine is a 2nd generation antihistamine and is used to manage symptoms of allergic rhinitis, wheal formation, urticaria, and other allergic dermatologic conditions.
[A176435][A176438][L8486]

Also known as(133)

Loratadina

Loratadine

Loratadinum

H1-R

H1R

HH1R

Eag homolog

Eag-related protein 1

Dosage forms(102)

Tablet, chewable (Buccal) — 10 mg

Tablet, film coated, extended release (Oral)

Solution (Oral) — 1.000 mg

Tablet, film coated (Oral)

Kit (Transdermal)

Tablet, effervescent (Oral)

Tablet, orally disintegrating (Oral)

Suspension (Oral) — 1 mg/ml

Molecular properties(18)

Drug interactions(716)

Known interactions with other medications. Always consult a healthcare professional.

Reserpine

Moderate

DB00206

Reserpine may decrease the excretion rate of Loratadine which could result in a higher serum level.

Check this interaction

Progesterone

Moderate

DB00396

Progesterone may decrease the excretion rate of Loratadine which could result in a higher serum level.

Check this interaction

Bosentan

Moderate

DB00559

Bosentan may decrease the excretion rate of Loratadine which could result in a higher serum level.

Check this interaction

Tamoxifen

Moderate

DB00675

Tamoxifen may decrease the excretion rate of Loratadine which could result in a higher serum level.

Check this interaction

Ethinylestradiol

Moderate

DB00977

Ethinylestradiol may decrease the excretion rate of Loratadine which could result in a higher serum level.

Check this interaction

Glyburide

Moderate

DB01016

Glyburide may decrease the excretion rate of Loratadine which could result in a higher serum level.

Check this interaction

Ursodeoxycholic acid

Moderate

DB01586

Ursodeoxycholic acid may decrease the excretion rate of Loratadine which could result in a higher serum level.

Check this interaction

Cholic Acid

Moderate

DB02659

Cholic Acid may decrease the excretion rate of Loratadine which could result in a higher serum level.

Check this interaction

Simeprevir

Moderate

DB06290

Simeprevir may decrease the excretion rate of Loratadine which could result in a higher serum level.

Check this interaction

Lenvatinib

Moderate

DB09078

Lenvatinib may decrease the excretion rate of Loratadine which could result in a higher serum level.

Check this interaction

Valinomycin

Moderate

DB14057

Valinomycin may decrease the excretion rate of Loratadine which could result in a higher serum level.

Check this interaction

Fusidic acid

Moderate

DB02703

Fusidic acid may decrease the excretion rate of Loratadine which could result in a higher serum level.

Check this interaction

Cyclosporine

Moderate

DB00091

Cyclosporine may decrease the excretion rate of Loratadine which could result in a higher serum level.

Check this interaction

Erythromycin

Unknown severity

DB00199

The serum concentration of Loratadine can be increased when it is combined with Erythromycin.

Check this interaction

Chlorpromazine

Moderate

DB00477

Chlorpromazine may decrease the excretion rate of Loratadine which could result in a higher serum level.

Check this interaction

Cimetidine

Moderate

DB00501

Cimetidine may decrease the excretion rate of Loratadine which could result in a higher serum level.

Check this interaction

Quinidine

Moderate

DB00908

Quinidine may decrease the excretion rate of Loratadine which could result in a higher serum level.

Check this interaction

Nifedipine

Moderate

DB01115

Loratadine may decrease the excretion rate of Nifedipine which could result in a higher serum level.

Check this interaction

Olmesartan

Moderate

DB00275

Olmesartan may decrease the excretion rate of Loratadine which could result in a higher serum level.

Check this interaction

Pralsetinib

Moderate

DB15822

Pralsetinib may decrease the excretion rate of Loratadine which could result in a higher serum level.

Check this interaction

Benzylpenicilloyl polylysine

Moderate

DB00895

Loratadine may decrease effectiveness of Benzylpenicilloyl polylysine as a diagnostic agent.

Check this interaction

Betahistine

Moderate

DB06698

The therapeutic efficacy of Betahistine can be decreased when used in combination with Loratadine.

Check this interaction

Amphetamine

Moderate

DB00182

Amphetamine may decrease the sedative activities of Loratadine.

Check this interaction

Phentermine

Moderate

DB00191

Phentermine may decrease the sedative activities of Loratadine.

Check this interaction

Benzphetamine

Moderate

DB00865

Benzphetamine may decrease the sedative activities of Loratadine.

Check this interaction

Diethylpropion

Moderate

DB00937

Diethylpropion may decrease the sedative activities of Loratadine.

Check this interaction

Lisdexamfetamine

Moderate

DB01255

Lisdexamfetamine may decrease the sedative activities of Loratadine.

Check this interaction

Mephentermine

Moderate

DB01365

Mephentermine may decrease the sedative activities of Loratadine.

Check this interaction

MMDA

Moderate

DB01442

MMDA may decrease the sedative activities of Loratadine.

Check this interaction

Midomafetamine

Moderate

DB01454

Midomafetamine may decrease the sedative activities of Loratadine.

Check this interaction

2,5-Dimethoxy-4-ethylamphetamine

Moderate

DB01467

2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Loratadine.

Check this interaction

Brolamfetamine

Moderate

DB01484

4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Loratadine.

Check this interaction

Tenamfetamine

Moderate

DB01509

Tenamfetamine may decrease the sedative activities of Loratadine.

Check this interaction

Chlorphentermine

Moderate

DB01556

Chlorphentermine may decrease the sedative activities of Loratadine.

Check this interaction

Methylenedioxyethamphetamine

Moderate

DB01566

Methylenedioxyethamphetamine may decrease the sedative activities of Loratadine.

Check this interaction

Dextroamphetamine

Moderate

DB01576

Dextroamphetamine may decrease the sedative activities of Loratadine.

Check this interaction

Metamfetamine

Moderate

DB01577

Metamfetamine may decrease the sedative activities of Loratadine.

Check this interaction

Iofetamine I-123

Moderate

DB09480

Iofetamine I-123 may decrease the sedative activities of Loratadine.

Check this interaction

Ritobegron

Moderate

DB12080

Ritobegron may decrease the sedative activities of Loratadine.

Check this interaction

Mephedrone

Moderate

DB13108

Mephedrone may decrease the sedative activities of Loratadine.

Check this interaction

Methoxyphenamine

Moderate

DB13624

Methoxyphenamine may decrease the sedative activities of Loratadine.

Check this interaction

Gepefrine

Moderate

DB13703

Gepefrine may decrease the sedative activities of Loratadine.

Check this interaction

2,5-Dimethoxy-4-ethylthioamphetamine

Moderate

DB13940

2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Loratadine.

Check this interaction

Phendimetrazine

Moderate

DB01579

Phendimetrazine may decrease the sedative activities of Loratadine.

Check this interaction

Rosiglitazone

Moderate

DB00412

The metabolism of Rosiglitazone can be decreased when combined with Loratadine.

Check this interaction

Torasemide

Moderate

DB00214

The metabolism of Torasemide can be decreased when combined with Loratadine.

Check this interaction

Dapsone

Moderate

DB00250

The metabolism of Dapsone can be decreased when combined with Loratadine.

Check this interaction

Morphine

Moderate

DB00295

The metabolism of Morphine can be decreased when combined with Loratadine.

Check this interaction

Sulfadiazine

Moderate

DB00359

The metabolism of Sulfadiazine can be decreased when combined with Loratadine.

Check this interaction

Cyclophosphamide

Moderate

DB00531

The metabolism of Cyclophosphamide can be decreased when combined with Loratadine.

Check this interaction

Showing 50 of 716 interactions

Toxicity & overdose

Second generation antihistamines such as loratadine have very few adverse effects; however, insomnia, headache, fatigue, drowsiness and rash have been reported.
[A176441]
Symptoms of loratadine overdose include gastrointestinal side effects, agitation, drowsiness, tachycardia, and headache.
[A176441]
It is advised to obtain an ECG in the event of loratadine overdose.
[A176441]

How it works

Mechanism of action

Histamine release is a key mediator in allergic rhinitis and urticaria.[A185312][A176441][A175060] As a result, loratadine exerts it's effect by targeting H1 histamine receptors.

Loratadine binds to H1 histamine receptors found on the surface of epithelial cells, endothelial cells, eosinophils, neutrophils, airway cells, and vascular smooth muscle cells among others.[A176441] H1 histamine receptors fall under the wider umbrella of G-protein coupled receptors, and exist in a state of equilibrium between the active and inactive forms.[A176441][A175060] Histamine binding to the H1-receptor facilitates cross linking between transmembrane domains III and V, stabilizing the active form of the receptor.[A176441][A175060] On the other hand, antihistamines bind to a different site on the H1 receptor favouring the inactive form.[A176441][A175060]

Hence, loratadine can more accurately be classified as an "inverse agonist" as opposed to a "histamine antagonist", and can prevent or reduce the severity of histamine mediated symptoms.[A176441][A175060][L8486]

Pharmacodynamics

Like other 2nd generation antihistamines, loratadine is selective for peripheral H1 receptors.[A5506] Loratadine does not penetrate effectively into the central nervous system and has poor affinity for CNS H1-receptors.[A5506] These qualities result in a lack of CNS depressant effects such as drowsiness, sedation, and impaired psychomotor function.[A5506]

Pharmacokinetics

How the body processes this drug — absorption, distribution, metabolism, and elimination

Absorption

Loratadine is rapidly absorbed and achieves peak plasma concentration in 1-2 hours, while it's main metabolite achieves peak plasma concentration in 3-4 hours.
[A176438]

In the rapid dissolve formulation, the pharmacokinetic parameters of loratadine are as follows[L8486]: Cmax = 2.56 ng/ml, Tmax = 1.14 hrs, AUC = 6.14 ng x hr/ml.

In the rapid dissolve formulation, the pharmacokinetic parameters of descarboethoxyloratadine are as follows[L8486]: Cmax = 3.72 ng/ml, Tmax = 1.97 hr, AUC = 49.1 ng x hr/ml.

In the conventional formulation, the pharmacokinetic parameters of loratadine are as follows[L8486]: Cmax = 2.11 ng/ml, Tmax = 1.00 hr, AUC = 4.64 ng x hr/ml

In the conventional formulation, the pharmacokinetic parameters of descarboethoxyloratadine are as follows[L8486]: Cmax = 3.66 ng/ml, Tmax = 1.97 hr, AUC = 48.4 ng x hr/ml

Half-life

The elimination half life is approximately 10 hours for loratadine and 20 hours for descarboethoxyloratadine.
[A176438]

Protein binding

97 - 99% of the loratadine is bound to plasma proteins.
[L8486]

Volume of distribution

The volume of distribution of loratadine is 120 L/Kg.
[L8618]

Metabolism

Loratadine undergoes extensive first pass metabolism in the liver and is primarily metabolized by CYP3A4, CYP2D6, CYP1A1 and CYP2C19. Less involved CYP enzymes include CYP1A2, CYP2B6, CYP2C8, CYP2C9 and CYP3A5.
[A38842][A176444]
CYP3A4 and CYP2D6 are mainly responsible for metabolizing loratadine to descarboethoxyloratadine.
[A176444]
This primary metabolite is 4 times more pharmacologically active than loratadine.
[A176438]

In addition, a study demonstrates that descarboethoxyloratadine is first glucuronidated by UGT2B10, then hydroxylated by CYP2C8 to form 3-hydroxydesloratadine.
[A185855]
Further glucuronidation of 3-hydroxydesloratadine facilitates excretion.
[A185843]

Route of elimination

Over a 10 day period, 40% of loratadine is excreted in the urine, and 42% is eliminated in the faeces.
[L8486]

Clearance

The clearance of loratadine after single oral doses of 20 mg and 40 mg are 12 L/h/kg and 9 L/h/kg respectively.
[A5506]

P-glycoprotein is involved in the clearance of many 2nd generation antihistamines, including loratadine, from the central nervous system. 1st generation antihistamines are not cleared by P-glycoprotein, which may help explain why they have a different central nervous system adverse effect profile compared to their 2nd generation counterparts.
[L8618][A175075]
It appears that an antihistamine with higher affinity for p-glycoprotein will have a lower incidence of CNS adverse effects.
[A175072]

Drug targets(2)

Proteins and enzymes this drug interacts with in the body

Histamine H1 receptor

BE0000442

HRH1

antagonist

Specific functionhistamine receptor activity

Cellular location

Cell membrane

General function & pharmacology

G-protein-coupled receptor for histamine, a biogenic amine that functions as an immune modulator and a neurotransmitter .
PMID:33828102 PMID:8280179
Through the H1 receptor, histamine mediates the contraction of smooth muscles and increases capillary permeability due to contraction of terminal venules. Also mediates neurotransmission in the central nervous system and thereby regulates circadian rhythms, emotional and locomotor activities as well as cognitive functions (By similarity)

Voltage-gated inwardly rectifying potassium channel KCNH2

BE0000090

KCNH2

antagonist

Specific functiondelayed rectifier potassium channel activity

Cellular location

Cell membrane

General function & pharmacology

Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel .
PMID:10219239 PMID:10753933 PMID:10790218 PMID:10837251 PMID:11997281 PMID:12063277 PMID:18559421 PMID:22314138 PMID:22359612 PMID:26363003 PMID:27916661 PMID:9230439 PMID:9351446 PMID:9765245

Channel properties are modulated by cAMP and subunit assembly .
PMID:10837251
Characterized by unusual gating kinetics by producing relatively small outward currents during membrane depolarization and large inward currents during subsequent repolarization which reflect a rapid inactivation during depolarization and quick recovery from inactivation but slow deactivation (closing) during repolarization .
PMID:10219239 PMID:10753933 PMID:10790218 PMID:10837251 PMID:11997281 PMID:12063277 PMID:18559421 PMID:22314138 PMID:22359612 PMID:26363003 PMID:27916661 PMID:9230439 PMID:9351446 PMID:9765245

Forms a stable complex with KCNE1 or KCNE2, and that this heteromultimerization regulates inward rectifier potassium channel activity PMID:10219239 PMID:9230439

Metabolizing enzymes(13)

Enzymes involved in drug metabolism — important for understanding drug interactions

Enzyme activity key

substrate

inhibitor

inducer

CYP3A4Cytochrome P450 3A4

substrate

inhibitor

CYP2D6Cytochrome P450 2D6

substrate

inhibitor

CYP1A1Cytochrome P450 1A1

substrate

CYP2C19Cytochrome P450 2C19

substrate

inhibitor

CYP2C8Cytochrome P450 2C8

substrate

inhibitor

CYP1A2Cytochrome P450 1A2

substrate

CYP2B6Cytochrome P450 2B6

substrate

CYP2C9Cytochrome P450 2C9

substrate

CYP3A5Cytochrome P450 3A5

substrate

UGT2B10UDP-glucuronosyltransferase 2B10

UGT1A1UDP-glucuronosyltransferase 1A1

UGT1A3UDP-glucuronosyltransferase 1A3

UGT2B15UDP-glucuronosyltransferase 2B15

Transporters(2)

Proteins that transport this drug across cell membranes

ATP-dependent translocase ABCB1

BE0001032

ABCB1

substrate

inhibitor

Specific functionABC-type xenobiotic transporter activity

Cellular location

Cell membrane

General function & pharmacology

Translocates drugs and phospholipids across the membrane .
PMID:2897240 PMID:35970996 PMID:8898203 PMID:9038218 PMID:35507548

Catalyzes the flop of phospholipids from the cytoplasmic to the exoplasmic leaflet of the apical membrane. Participates mainly to the flop of phosphatidylcholine, phosphatidylethanolamine, beta-D-glucosylceramides and sphingomyelins .
PMID:8898203
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells PMID:2897240 PMID:35970996 PMID:9038218

Bile salt export pump

BE0000703

ABCB11

substrate

Specific functionABC-type bile acid transporter activity

Cellular location

Apical cell membrane

General function & pharmacology

Catalyzes the transport of the major hydrophobic bile salts, such as taurine and glycine-conjugated cholic acid across the canalicular membrane of hepatocytes in an ATP-dependent manner, therefore participates in hepatic bile acid homeostasis and consequently to lipid homeostasis through regulation of biliary lipid secretion in a bile salts dependent manner .
PMID:15791618 PMID:16332456 PMID:18985798 PMID:19228692 PMID:20010382 PMID:20398791 PMID:22262466 PMID:24711118 PMID:29507376 PMID:32203132

Transports taurine-conjugated bile salts more rapidly than glycine-conjugated bile salts .
PMID:16332456
Also transports non-bile acid compounds, such as pravastatin and fexofenadine in an ATP-dependent manner and may be involved in their biliary excretion PMID:15901796 PMID:18245269

Biological pathways(1)

Loratadine H1-Antihistamine Action

Involved compounds

Calcium,Loratadine

Scientific references(16)

See S.

Desloratadine efficacious in allergic rhinitis.

Inpharma Weekly

20071586(1):10-10. doi: 10.1007/bf03272618

PMID: 14655812 DOI: 10.1007/bf03272618

Menardo J.L., Horak F., Danzig M.R., Czarlewski W.

A review of loratadine in the treatment of patients with allergic bronchial asthma.

Clinical Therapeutics

199719(6):1278-1293. doi: 10.1016/s0149-2918(97)80005-7

PMID: 9444440 DOI: 10.1016/s0149-2918(97)80005-7

Howarth P.H.

Histamine and asthma: an appraisal based on specific H<sub>1</sub>‐receptor antagonism.

Clinical & Experimental Allergy

199020(s2):31-41. doi: 10.1111/j.1365-2222.1990.tb02459.x

PMID: 1977506 DOI: 10.1111/j.1365-2222.1990.tb02459.x

Baroody F.M., Naclerio R.M.

Antiallergic effects of H<sub>1</sub>‐receptor antagonists.

Allergy

200055(s64):17-27. doi: 10.1034/j.1398-9995.2000.00803.x

PMID: 11291777 DOI: 10.1034/j.1398-9995.2000.00803.x

Tenn M.W., Steacy L.M., Ng C.C., Ellis A.K.

Onset of action for loratadine tablets for the symptomatic control of seasonal allergic rhinitis in adults challenged with ragweed pollen in the Environmental Exposure Unit: a post hoc analysis of total symptom score.

Allergy Asthma Clinical Immunology

2018 Jan 1614:5. doi: 10.1186/s13223-017-0227-4. eCollection 2018

PMID: 29371864 DOI: 10.1186/s13223-017-0227-4

Barenholtz H.A., McLeod D.C.

Loratadine: A Nonsedating Antihistamine with Once-Daily Dosing.

DICP

198923(6):445-450. doi: 10.1177/106002808902300601

PMID: 2525847 DOI: 10.1177/106002808902300601

Randall K.L., Hawkins C.A.

Antihistamines and allergy.

Aust Prescr

2018 Apr41(2):41-45. doi: 10.18773/austprescr.2018.013. Epub 2018 Apr 3

PMID: 29670310 DOI: 10.18773/austprescr.2018.013

Church M.K., Church D.S.

Pharmacology of antihistamines.

Indian Journal Dermatology

2013 May58(3):219-24. doi: 10.4103/0019-5154.110832

PMID: 23723474 DOI: 10.4103/0019-5154.110832

Clissold S.P., Sorkin E.M., Goa K.L.

Loratadine.

Drugs

198937(1):42-57. doi: 10.2165/00003495-198937010-00003

PMID: 2523301 DOI: 10.2165/00003495-198937010-00003

Ghosal A., Gupta S., Ramanathan R., Yuan Y., Lu X., Su A.D., Alvarez N., Zbaida S., Chowdhury S.K., Alton K.B.

Metabolism of Loratadine and Further Characterization of Its In Vitro Metabolites.

Drug Metabolism Letters

20093(3):162-170. doi: 10.2174/187231209789352067

PMID: 19702548 DOI: 10.2174/187231209789352067

Zhang Y.F., Chen X.Y., Zhong D.F., Dong Y.M.

Pharmacokinetics and pharmacodynamics of single and multiple doses of prasugrel in healthy native Chinese subjects.

Acta Pharmacologica Sinica

201233(11):1395-1400. doi: 10.1038/aps.2012.120

PMID: 12852841 DOI: 10.1038/aps.2012.120

Naclerio R.M.

The role of histamine in allergic rhinitis.

Journal Allergy Clinical Immunology

1990 Oct86(4 Pt 2):628-32. doi: 10.1016/s0091-6749(05)80227-1

PMID: 1977783 DOI: 10.1016/s0091-6749(05)80227-1

Obradovic T., Dobson G.G., Shingaki T., Kungu T., Hidalgo I.J.

Assessment of the first and second generation antihistamines brain penetration and role of P-glycoprotein.

Pharmaceutical Research

2007 Feb24(2):318-27. doi: 10.1007/s11095-006-9149-4. Epub 2006 Dec 19

PMID: 17180728 DOI: 10.1007/s11095-006-9149-4

Conen S., Theunissen E.L., Vermeeren A., van Ruitenbeek P., Stiers P., Mehta M.A., Toennes S.W., Ramaekers J.G.

The role of P-glycoprotein in CNS antihistamine effects.

Psychopharmacology (Berl)

2013 Sep229(1):9-19. doi: 10.1007/s00213-013-3075-z. Epub 2013 Apr 7

PMID: 23564211 DOI: 10.1007/s00213-013-3075-z

Kazmi F., Barbara J.E., Yerino P., Parkinson A.

A long-standing mystery solved: the formation of 3-hydroxydesloratadine is catalyzed by CYP2C8 but prior glucuronidation of desloratadine by UDP-glucuronosyltransferase 2B10 is an obligatory requirement.

Drug Metabolism and Disposition

2015 Apr43(4):523-33. doi: 10.1124/dmd.114.062620. Epub 2015 Jan 16

PMID: 25595597 DOI: 10.1124/dmd.114.062620

Aratyn-Schaus Y., Ramanathan R.

Advances in high-resolution MS and hepatocyte models solve a long-standing metabolism challenge: the loratadine story.

Bioanalysis

2016 Aug8(16):1645-62. doi: 10.4155/bio-2016-0094. Epub 2016 Jul 27

PMID: 27460981 DOI: 10.4155/bio-2016-0094

ATC classification(1 code)

ATC R06AX13

Affected organisms(1)

Humans and other mammals

International brands(17)

Experimental properties(2)

External resources(2)

RxList Drugs.com

Commercial products(884)

Chemical identifiers

CAS, UNII, InChI Key and database cross-references

Show

Linked compound data from DrugBank Open Data (CC BY-NC 4.0)

Loratadine

DB00455

CAS number

79794-75-5

UNII (FDA)

7AJO3BO7QN

InChI Key (molecular fingerprint)

JCCNYMKQOSZNPW-UHFFFAOYSA-N

Additional database identifiers

Drugs Product Database (DPD)

1299

ChEBI

6538

PubChem Compound

3957

PubChem Substance

46507853

KEGG Drug

D00364

ChemSpider

3820

BindingDB

22876

PharmGKB

PA450266

Therapeutic Targets Database

DAP000101

Wikipedia

Loratadine

ChEMBL

CHEMBL998

ZINC

ZINC000000537931

RxCUI

28889

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5182

GenAtlas

HRH1

GeneCards

HRH1

GenBank Gene Database

Z34897

GenBank Protein Database

510296

IUPHAR

262

Guide to Pharmacology

262

UniProtKB

P35367

UniProt Accession

HRH1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6251

GenAtlas

KCNH2

GeneCards

KCNH2

GenBank Gene Database

U04270

GenBank Protein Database

487738

IUPHAR

572

Guide to Pharmacology

572

UniProtKB

Q12809

UniProt Accession

KCNH2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2637

GenAtlas

CYP3A4

GeneCards

CYP3A4

GenBank Gene Database

M18907

Guide to Pharmacology

1337

UniProtKB

P08684

UniProt Accession

CP3A4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2625

GenAtlas

CYP2D6

GeneCards

CYP2D6

GenBank Gene Database

M20403

GenBank Protein Database

181350

Guide to Pharmacology

1329

UniProtKB

P10635

UniProt Accession

CP2D6_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2595

GeneCards

CYP1A1

GenBank Gene Database

K03191

GenBank Protein Database

181276

Guide to Pharmacology

1318

UniProtKB

P04798

UniProt Accession

CP1A1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2621

GeneCards

CYP2C19

GenBank Gene Database

M61854

GenBank Protein Database

181344

Guide to Pharmacology

1328

UniProtKB

P33261

UniProt Accession

CP2CJ_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2622

GenAtlas

CYP2C8

GeneCards

CYP2C8

GenBank Gene Database

M17397

Guide to Pharmacology

1325

UniProtKB

P10632

UniProt Accession

CP2C8_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2596

GenAtlas

CYP1A2

GeneCards

CYP1A2

GenBank Gene Database

Z00036

Guide to Pharmacology

1319

UniProtKB

P05177

UniProt Accession

CP1A2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2615

GeneCards

CYP2B6

GenBank Gene Database

M29874

GenBank Protein Database

181296

Guide to Pharmacology

1324

UniProtKB

P20813

UniProt Accession

CP2B6_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2623

GenAtlas

CYP2C9

GeneCards

CYP2C9

GenBank Gene Database

AY341248

Guide to Pharmacology

1326

UniProtKB

P11712

UniProt Accession

CP2C9_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2638

GenAtlas

CYP3A5

GeneCards

CYP3A5

GenBank Gene Database

J04813

GenBank Protein Database

181346

Guide to Pharmacology

1338

UniProtKB

P20815

UniProt Accession

CP3A5_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:12544

GeneCards

UGT2B10

UniProtKB

P36537

UniProt Accession

UDB10_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:12530

GeneCards

UGT1A1

GenBank Gene Database

M57899

GenBank Protein Database

184473

Guide to Pharmacology

2990

UniProtKB

P22309

UniProt Accession

UD11_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:12535

GeneCards

UGT1A3

GenBank Gene Database

M84127

GenBank Protein Database

340135

UniProtKB

P35503

UniProt Accession

UD13_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:12546

GeneCards

UGT2B15

UniProtKB

P54855

UniProt Accession

UDB15_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:40

GenAtlas

ABCB1

GeneCards

ABCB1

GenBank Gene Database

M14758

GenBank Protein Database

307180

Guide to Pharmacology

768

UniProtKB

P08183

UniProt Accession

MDR1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:42

GenAtlas

ABCB11

GeneCards

ABCB11

GenBank Gene Database

AF091582

GenBank Protein Database

3873243

Guide to Pharmacology

778

UniProtKB

O95342

UniProt Accession

ABCBB_HUMAN

International reference pricing

34 formulations

Reference pricing from DrugBank. Prices are indicative and may not reflect current UK costs.

From $0.07/tablet

To $29.99/box

Allergy relief 10 mg tablet

$0.07/tablet

Qc loratadine 10 mg tablet

$0.08/tablet

CVS Pharmacy allergy relief 10 mg tablet

$0.44/tablet

Loratadine 10 mg tablet

$0.47/tablet

CVS Pharmacy loratadine 10 mg tablet

$0.52/tablet

Source: DrugBank. Used under CC BY-NC 4.0 academic licence for non-commercial purposes.

Patent information

All patents expired, 1 expired

6132758

United States

Approved 17 Oct 2000 · Expires 1 Jun 2018

Expired

Patent protection has expired — generic versions may be available.

Source: DrugBank · CC BY-NC 4.0. Patent data sourced from national patent offices. Expiry dates may not reflect extensions, regulatory exclusivity periods, or legal challenges.

DrugBank citations

If you use DrugBank data in your research, please cite the following publications:

Knox C., Wilson M., Klinger C.M., et al

DrugBank 6.

0: the DrugBank Knowledgebase for 2024

Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275

PMID: 37953279

Wishart D.S., Feunang Y.D., Guo A.C., et al

DrugBank 5.

0: a major update to the DrugBank database for 2018

Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082

PMID: 29126136

Show earlier publications

Law V., Knox C., Djoumbou Y., et al

DrugBank 4.

0: shedding new light on drug metabolism

Nucleic Acids Res. 2014 Jan 142(1):D1091-7

PMID: 24203711

Knox C., Law V., Jewison T., et al

DrugBank 3.

0: a comprehensive resource for 'omics' research on drugs

Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41

PMID: 21059682

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a knowledgebase for drugs, drug actions and drug targets.

Nucleic Acids Research

2008 Jan36(Database issue):D901-6

PMID: 18048412

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a comprehensive resource for in silico drug discovery and exploration.

Nucleic Acids Research

2006 Jan 134(Database issue):D668-72

PMID: 16381955

Source: go.drugbank.comCC BY-NC 4.0

Updated 26 days ago(8 Mar 2026)

Back to medicines

Loratadine 10mg tablets

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

WHO defined daily dose (DDD)

British National Formulary

NICE clinical guidance(1)

Pharmacy stock checkers

Supply & product information

NHS UK identifiers

International identifiers

Browse tools

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Volume of distribution

Metabolism

Elimination

Clearance

Clinical essentials

Pharmacology

Deep science
18

Chemical identifiers

Loratadine

Additional database identifiers

International reference pricing

Patent information

DrugBank citations

Loratadine 10mg tablets

Safety & regulatory

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

Brand versions and licensed products

NHS reimbursement price

WHO defined daily dose (DDD)

Medicines like this

Prescribing statistics

Guidance (NICE / BNF)

British National Formulary

NICE clinical guidance(1)

Availability, stocks & shortages

Pharmacy stock checkers

Supply & product information

Professional identifiers

NHS UK identifiers

International identifiers

Browse tools

Clinical trials

DrugBank data

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Volume of distribution

Metabolism

Elimination

Clearance

Clinical essentials

Pharmacology

Deep science18

Chemical identifiers

Loratadine

Additional database identifiers

International reference pricing

Patent information

DrugBank citations

Deep science
18